(Q53668957)

17 May 2018

title

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. (English)

1 reference

17 May 2018

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

1 reference

2

1 reference

17 May 2018

Gabe S Sonke

object named as

Gabe S Sonke

6

0 references

Barbara Schmalfeldt

13

object named as

Barbara Schmalfeldt

1 reference

17 May 2018

Peter Vuylsteke

9

object named as

Peter Vuylsteke

1 reference

17 May 2018

author name string

Amit M Oza

1

1 reference

17 May 2018

Ana Oaknin Benzaquen

3

1 reference

17 May 2018

Christopher Poole

4

1 reference

17 May 2018

Ron H J Mathijssen

5

1 reference

17 May 2018

Nicoletta Colombo

7

1 reference

17 May 2018

Jiří Špaček

8

1 reference

17 May 2018

Holger Hirte

10

1 reference

17 May 2018

Sven Mahner

11

1 reference

17 May 2018

Marie Plante

12

1 reference

17 May 2018

Helen Mackay

14

1 reference

17 May 2018

Jacqui Rowbottom

15

1 reference

17 May 2018

Elizabeth S Lowe

16

1 reference

17 May 2018

Brian Dougherty

17

1 reference

17 May 2018

J Carl Barrett

18

1 reference

17 May 2018

Michael Friedlander

19

1 reference

17 May 2018

publication date

4 December 2014

1 reference

17 May 2018

Lancet Oncology Commission

published in

1 reference

17 May 2018

volume

16

1 reference

17 May 2018

page(s)

87-97

1 reference

17 May 2018

issue

1

1 reference

17 May 2018

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Optimal chemotherapy treatment for women with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Management of platinum-sensitive recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971135-0

7 January 2021

10.1016/S1470-2045(14)71135-0

Identifiers

DOI

1 reference

17 May 2018

PubMed ID

25481791

1 reference

17 May 2018